logo
He thought he was too old to be an EMT. At 76, he's saved countless lives.

He thought he was too old to be an EMT. At 76, he's saved countless lives.

Washington Post6 days ago
The day a man collapsed in a parking lot in Bethesda, Maryland, EMT Ed Levien rushed in an ambulance to the scene, where the injured man repeatedly called for Jesus.
'Jesus isn't here,' Levien recalled telling him. 'You've got to put up with me.'
The man looked at Levien's mustached face, his thinning gray hair and his round glasses and replied, 'Okay, Pops.'
That's how Levien, one of the oldest EMTs in Maryland, got his nickname a few years ago in the volunteer job that — to his surprise — has become an unintended second career and reshaped his identity.
'I never had an impact on anyone until I started doing this,' Levien, who previously worked in advertising, told The Washington Post.
Levien began working as a volunteer EMT when he was 65 years old, far surpassing the age of his colleagues at the Bethesda-Chevy Chase Rescue Squad. After recovering from an unexpected injury — with the help of strangers — he decided to help others for as long as his body would allow.
In the past 12 years, Levien, 76, has responded to more than 3,300 emergency calls and worked more than 13,000 unpaid hours. He has helped deliver a baby, treated potentially fatal wounds and been a calming voice for panicked families.
All the while he was wearing hearing aids and managing his chronic lung condition, emphysema.
Levien stopped working as an EMT in April, struggling with the physical aspects of the job, but he said he still wanted to be useful at the rescue squad — so he now trains new members, fills ambulances with medical supplies and schedules shifts.
Levien's journey to becoming an EMT began with a moped crash on his honeymoon in Bermuda in August 2000, which broke his left arm and severed a nerve. He couldn't move his dominant arm for about two years, Levien said, and endured crippling pain for more than a decade.
Levien struggled to cut chicken and steak at restaurants, tie his shoes and get dressed. He was surprised but grateful when strangers approached his restaurant tables to cut his meat and family members and friends bent down to tie his shoes.
Feeling vulnerable shifted his perspective, and Levien started becoming more charitable himself. If he saw someone struggling to cross a street or enter a door, he said, he would help. In 2011, Levien had a neurostimulator inserted into his chest to alleviate the chronic pain in his left arm, broadening his opportunities to help others.
In 2013, Levien drove by a digital billboard in front of the Bethesda-Chevy Chase Rescue Squad's headquarters that said the group was looking for volunteers. When Levien called, he suggested he could be a dispatcher because he thought, at 64, he was too old to be an EMT. But employees said there wasn't an age limit.
He did six months of medical training among a handful of 20- and 30-year-olds. Levien demonstrated his physical fitness by working with a partner to carry a roughly 100-pound mannequin up the rescue's stairs, across a hallway and back down the stairs in less than 10 minutes.
Soon, Levien was taking on two 12-hour shifts a week and responding to emergency calls.
'He was given another lease on life,' said Levien's wife, Robin. 'And it didn't go to waste.'
During one of his first calls, Levien helped a woman deliver a baby, whom the mother gave the same first initial as Levien.
Another time, when a man ruptured an artery in his groin, Levien lay on top of him to apply pressure and slow the bleeding, and his colleagues lifted them together on a stretcher into an ambulance. The man survived, Levien said.
While many first responders exchange basic greetings with patients, Levien was quick to add levity when appropriate by cracking jokes. Levien's age and life experience helped him build rapport with patients, especially the elderly and children, his colleagues said.
When Kevin Wallace, 27, began working with Levien near the end of 2022, he said he thought he would 'babysit the old guy.' But a few months in, they received a call from a panicked mother who said her child was suffering a seizure. Wallace rushed to grab medical supplies as the men responded to the call. Levien calmly and correctly predicted from the symptoms that the child's seizure wasn't deadly, Wallace said.
Wallace realized then that Levien knew what he was doing.
Sometimes when Levien is out at dinner, he said, strangers approach and thank him for saving their family members' lives.
'You sleep well at night,' Levien said, 'because what you're doing truly makes a difference.'
Levien and his colleagues still joked about his age and fashion choices. They would point out that he was the only one wearing suspenders with his uniform each shift.
Before responding to calls at senior facilities, Levien told his colleagues that their primary job was to ensure employees there didn't think he was a patient and give him his own bedroom.
While responding to a call at a townhouse during the coronavirus pandemic, Levien's colleague, Aaron Abramson, 27, said he would check on the patient himself. Levien asked why. Abramson, being protective of Levien, said he feared Levien would die if he got covid.
In addition to his 'Pops' nickname, Levien's colleagues call him 'Mr. Ed.'
'Some people thought he was a bit of a crazy old man,' said Abramson, who now works for the Baltimore City Fire Department. 'But I think for the most part, people really respected Ed.'
Levien helped save lives even when he wasn't on scene. He trained Daniel Edwards and his daughter, Ella, in emergency medicine at the firehouse. Years later, in December, the father and daughter saw someone in distress at a yoga studio, and gave them CPR.
'We were just doing exactly what we were trained to do in a pretty calm manner,' said Edwards, 51.
As Levien grew older, he struggled to pick up bodies and run up stairs with equipment to reach patients. Levien's final day as an EMT was April 30. The next day, Levien's colleagues wore suspenders for his retirement party.
Levien still trains new members, offers advice and restocks the rescue's six ambulances with equipment, including bandages, gloves, needles, suction tubes, toy ambulances for children and glucometers.
On a recent afternoon, a group of first responders was eating lunch when an alarm went off: Someone had fallen at an assisted-living facility. A few first responders jumped into an ambulance, and Levien watched as they left within a minute.
Levien misses going out on calls, he said, but he's still finding ways to help others. He routinely visits or calls his neighbors to check on their health.
Plus, every morning, Levien is reminded of his life's second passion when he drinks coffee from a gray and white mug his colleagues made that says 'POPS.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

The Best and Worst States To Have a Baby in 2025
The Best and Worst States To Have a Baby in 2025

Yahoo

time28 minutes ago

  • Yahoo

The Best and Worst States To Have a Baby in 2025

WalletHub looked at 31 key measures of cost and health care accessibility to put together the list. Fact checked by Sarah Scott Welcoming a baby is supposed to be a joyous time. For many obvious reasons, it is. But there are certain stressors that come with becoming a parent, or even adding to your family. A big one is the cost. And that can vary greatly depending on where your family lives. Pregnancy, childbirth, and postpartum care costs can average a total of $18,865, with out-of-pocket payments coming out to an average of $2,854, according to Health System Tracker, an online hub monitoring the U.S. health system. That's just for people in large group plans. Factor in unforeseen childbirth complications, rising child care costs, and no mandated federal paid parental leave in the country, and costs can quickly become a burden. A new report from personal finance company WalletHub looks at where families may be feeling it the most, by rating the best and worst places in the U.S. to have a baby. To come to its findings, the company examined 31 key measures of cost and health care accessibility, while also taking baby- and family-friendliness into account. 'The best states for having a baby minimize costs while providing top-notch care for both newborns and their mothers,' Chip Lupo, a WalletHub analyst, says in a statement. 'They also continue to be good environments for parents even long after the birth, with high-quality pediatric care, affordable and accessible child care, and a strong economic environment that makes providing for a child easier.' Best States To Have a Baby WalletHub looked at several factors such as delivery charges, annual infant care costs, infant and maternal mortality rates, number of physicians accessible, and child care costs. Massachusetts, which recently also ranked the best state to raise a family, topped this list for having the third-lowest infant mortality rate and eighth-lowest for maternal mortality. It has the best neonatal hospitals in the nation, while also offering the best leave policies. Further, the state has the sixth-lowest households with kids with food insecurity, and the second-highest number of kids under 3 with all seven recommended vaccines. Here is the full list of the top 10. Massachusetts North Dakota Minnesota New Hampshire Maine Rhode Island Vermont Washington Iowa District of Columbia Worst States To Have a Baby Mississippi Alabama Nevada South Carolina Georgia New Mexico Arkansas Florida Oklahoma West Virginia While it can feel discouraging if you live in a state that ranks on the lower side, it can be helpful to prepare for childbirth costs as much as possible. If you have insurance, stay with in-network providers and make sure to find out what your insurance company covers and what it doesn't. If you don't have health insurance, the Department of Health and Human Services can help you find reduced prenatal care. Always ask your health care provider any questions you have, even when it comes to tests they recommend. They may be able to offer options to manage and reduce costs, too. Read the original article on Parents Solve the daily Crossword

Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress
Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

Yahoo

time28 minutes ago

  • Yahoo

Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

Prioritizing development of RP-A501 (Danon disease), RP-A601 (PKP2-ACM), and RP-A701 (BAG3-DCM) to advance AAV cardiovascular gene therapy platform for sustained value creation FDA RMAT designation awarded to RP-A601 for PKP2-ACM; Engaging with FDA on pivotal trial design following encouraging initial Phase 1 data at ASGCT IND accepted and FDA Fast Track designation received for RP-A701 in BAG3-DCM program; Phase 1 trial start-up activities underway Organizational restructuring expected to reduce headcount by approximately 30% and lower 12-month cash burn by nearly 25% Chris Stevens appointed Chief Operating Officer Cash, cash equivalents and investments of approximately $271.5M; expected operational runway into the second quarter of 2027 CRANBURY, N.J., August 07, 2025--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the second quarter ending June 30, 2025. "The second quarter of 2025 marked an important inflection point for Rocket as we refined our strategic focus around our AAV cardiovascular gene therapy platform and took multiple decisive steps to strengthen our financial foundation and thoughtfully adjust to market dynamics. We are fortifying our path to sustained value creation by leaning into programs with the highest value, conserving cash, and driving an efficient, agile organization," said Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharmaceuticals. "With regulatory alignment to resolve the clinical hold for RP-A501 in Danon disease in progress, momentum building for RP-A601 in PKP2-ACM as it advances toward a pivotal Phase 2 trial, and RP-A701 preparing to enter the clinic for the treatment of BAG3-DCM, Rocket is positioned as the leader in the development of gene therapies for inherited cardiomyopathies. While we are pausing additional investments in the FA and PKD programs, we are deeply grateful and committed to the patient communities and are exploring strategic alternatives to advance these programs externally. Finally, our recent reorganization ensures we are appropriately resourced to execute on our near-term milestones with nearly two years of capital." Recent Pipeline and Operational Updates Investigation into the Serious Adverse Event (SAE) from the Phase 2 pivotal study of RP-A501 for Danon disease is ongoing. Rocket previously disclosed an SAE, related to clinical complications from capillary leak syndrome and unfortunately leading to the patient's death. In response, Rocket paused dosing and initiated a root cause analysis, focusing on the recent addition of a C3 inhibitor to the pre-treatment regimen. On May 23, 2025, FDA placed the trial on clinical hold for further evaluation. Rocket is actively working with FDA, independent safety monitors, and clinical experts to ensure patient safety and resume the trial. While the clinical hold remains in place, the company cannot provide guidance on trial completion timing. Actively engaging with FDA on the advancement of RP-A601 for PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM) in potential pivotal trial following initial positive Phase 1 data at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). In July, Rocket received FDA Regeneration Medicine Advanced Therapy (RMAT) designation for RP-A601 for PKP2-ACM. Initial Phase 1 data demonstrating encouraging safety and preliminary efficacy outcomes of RP-A601 for PKP2-ACM were presented at ASGCT in May 2025. Rocket is engaging with FDA on potential pivotal trial design to evaluate the efficacy and safety of RP-A601. Phase 1 trial start-up activities are underway for RP-A701 in BAG3-associated dilated cardiomyopathy (BAG3-DCM). In June, an Investigational New Drug (IND) application for RP-A701, an AAVrh.74-based gene therapy candidate for the treatment of BAG3-DCM, received clearance from FDA. RP-A701 was recently granted FDA Fast Track designation, designed to facilitate the development and expedite the review of therapies for serious or life-threatening conditions that fill an unmet medical need. This enables increased communication with FDA, the potential for accelerated approval, and permits a rolling Biologics License Application (BLA) review. The first-in-human Phase 1 clinical trial will be a multi-center, dose-escalation study designed to evaluate the safety, biological activity, and preliminary efficacy of RP-A701 in adults with BAG3-DCM. BAG3-DCM is a rare, inherited heart condition caused by mutations in the BAG3 gene, leading to early-onset, progressive heart failure due to impaired cardiac function, high morbidity, and premature mortality. Rocket estimates that the prevalence of BAG3-DCM in the U.S. is as many as 30,000 individuals. FDA review of limited additional Chemistry Manufacturing and Controls (CMC) information ongoing for KRESLADITM (marnetegragene autotemcel; marne-cel) for the treatment of severe leukocyte adhesion deficiency-I (LAD-I). Rocket previously disclosed that FDA requested limited additional CMC information to complete its review of KRESLADI to treat severe LAD-I. The Company continues to work with senior leaders and reviewers from FDA's Center for Biologics Evaluation and Research and submission of complete BLA to resolve Complete Response Letter is anticipated before the end of 2025. Ongoing strategic corporate restructuring and pipeline prioritization. As part of its broader strategic reorganization, Rocket implemented a workforce reduction of approximately 30%, across all functions, to align with a pipeline prioritization plan focused exclusively on its AAV cardiovascular gene therapy platform. This restructuring, together with other cost-saving measures, is expected to reduce operating expenses by nearly 25% over the next 12 months. The reorganization enables the company to focus on its late‑stage AAV gene therapy programs in Danon disease, PKP2‑ACM, and BAG3‑DCM, while advancing regulatory activities for KRESLADI™ in severe LAD‑I. As part of this realignment, Rocket is pausing additional investments in its Fanconi Anemia (FA; RP-L102) and Pyruvate Kinase Deficiency (PKD; RP-L301) programs. The company continues to evaluate options to advance the FA program with health authorities in alignment with its refined strategic focus and broader corporate priorities. In July, Rocket appointed Chris Stevens as Chief Operating Officer. Chris Stevens is a highly seasoned executive with 25 years of experience across technical operations, product strategy, and general management, bringing immense commercial technical operations experience to Rocket. Stevens most recently served as the Executive Vice President and Chief Patient Supply Officer at Spark Therapeutics (subsidiary of Roche), where he successfully led teams across manufacturing, supply chain, quality, compliance, engineering, EHS, and facilities management, playing a key role in delivering gene therapies to patients. Second Quarter 2025 Financial Results Cash position. Cash, cash equivalents and investments as of June 30, 2025, were $271.5 million. Rocket expects such resources, excluding any potential proceeds from a Priority Review Voucher that may be granted upon FDA approval of KRESLADITM, will be sufficient to fund its operations into the second quarter of 2027. R&D expenses. Research and development expenses were $42.7 million for the three months ended June 30, 2025, compared to $46.3 million for the three months ended June 30, 2024. The decrease of $3.7 million in R&D expenses was primarily driven by decreases in manufacturing and development and direct material costs of $2.3 million, professional fees of $2.0 million and building supplies and consumables of $0.8 million, offset by an increase in clinical trial expenses of $1.2 million. G&A expenses. General and administrative expenses were $25.0 million for the three months ended June 30, 2025, compared to $27.4 million for the three months ended June 30, 2024. The decrease in G&A expenses was primarily driven by decreases in commercial preparation related expenses of $1.4 million and compensation and benefits expense of $0.9 million. Net loss. Net loss was $68.9 million or $0.62 per share (basic and diluted) for the three months ended June 30, 2025, compared to $69.6 million or $0.74 (basic and diluted) for the three months ended June 30, 2024. Shares outstanding. 107,884,420 shares of common stock were outstanding as of June 30, 2025. Restructuring Expenses and Financial Guidance Restructuring expenses. Approximately $3.5 million in restructuring and restructuring-related charges were incurred in the first half of 2025. About Rocket Pharmaceuticals, Pharmaceuticals, Inc. (NASDAQ: RCKT) is a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Rocket's innovative multi-platform approach allows us to design the optimal gene therapy for each indication, creating potentially transformative options that enable people living with devastating rare diseases to experience long and full lives. Rocket's adeno-associated viral (AAV) vector-based cardiovascular portfolio includes a late-stage clinical program for Danon Disease, a devastating heart failure condition resulting in thickening of the heart, and an early-stage clinical program for PKP2-arrhythmogenic cardiomyopathy (ACM), a life-threatening heart failure disease causing ventricular arrhythmias and sudden cardiac death. Rocket has also received IND clearance for its AAV-based gene therapy for BAG3-associated dilated cardiomyopathy (DCM), a heart failure condition that causes enlarged ventricles. Rocket's lentiviral (LV) vector-based hematology portfolio consists of late-stage programs for Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, Fanconi Anemia (FA), a difficult-to-treat genetic disease that leads to bone marrow failure (BMF) and potentially cancer, and Pyruvate Kinase Deficiency (PKD), a monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. For more information about Rocket, please visit and follow us on LinkedIn, YouTube, and X. Rocket Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements concerning Rocket's future expectations, plans and prospects that involve risks and uncertainties, as well as assumptions that, if they do not materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this release are forward-looking statements. You should not place reliance on these forward-looking statements, which often include words such as "could," "believe," "expect," "anticipate," "intend," "plan," "will give," "estimate," "seek," "will," "may," "suggest" or similar terms, variations of such terms or the negative of those terms. These forward-looking statements include, but are not limited to, statements concerning Rocket's ability to realize the intended benefits of the restructuring plan and reduction in workforce, expectations regarding the safety and effectiveness of product candidates that Rocket is developing to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), Danon Disease (DD) and other diseases, the expected timing and data readouts of Rocket's ongoing and planned clinical trials, the expected timing and outcome of Rocket's regulatory interactions and planned submissions, including the timing and outcome of the FDA's review of the additional CMC information that Rocket will provide in response to the FDA's request, the safety, effectiveness and timing of pre-clinical studies and clinical trials, Rocket's ability to establish key collaborations and vendor relationships for its product candidates, Rocket's ability to develop sales and marketing capabilities or enter into agreements with third parties to sell and market its product candidates, Rocket's ability to expand its pipeline to target additional indications that are compatible with its gene therapy technologies, Rocket's ability to transition to a commercial stage pharmaceutical company, and Rocket's expectation that its cash, cash equivalents and investments will be sufficient to fund its operations into the second quarter of 2027. There can be no assurance that the restructuring plan or the planned reduction in workforce will have the intended effect on the Company's operational results and strategic decisions, that any anticipated charges and any anticipated cost savings associated with the restructuring plan or the reduction in workforce will achieve their intended benefits. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Rocket's dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, unexpected expenditures, Rocket's competitors' activities, including decisions as to the timing of competing product launches, pricing and discounting, Rocket's ability to develop, acquire and advance product candidates into, enroll a sufficient number of patients into, and successfully complete, clinical studies, the integration of new executive team members and the effectiveness of the newly configured corporate leadership team, Rocket's ability to acquire additional businesses, form strategic alliances or create joint ventures and its ability to realize the benefit of such acquisitions, alliances or joint ventures, Rocket's ability to obtain and enforce patents to protect its product candidates, and its ability to successfully defend against unforeseen third-party infringement claims, as well as those risks more fully discussed in the section entitled "Risk Factors" in Rocket's Annual Report on Form 10-K for the year ended December 31, 2024, filed February 27, 2025 with the SEC and subsequent filings with the SEC including our Quarterly Reports on Form 10-Q. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 42,658 $ 46,345 $ 78,600 $ 91,572 General and administrative 25,020 27,367 53,466 49,515 Restructuring 3,471 - 3,471 - Total operating expenses 71,149 73,712 135,537 141,087 Loss from operations (71,149 ) (73,712 ) (135,537 ) (141,087 ) Interest expense (473 ) (471 ) (945 ) (942 ) Interest and other income, net 483 2,294 1,819 5,323 Accretion of discount on investments, net 2,220 2,243 4,410 5,006 Net loss (68,919 ) (69,646 ) (130,253 ) (131,700 ) Net loss per share - basic and diluted $ (0.62 ) $ (0.74 ) $ (1.18 ) $ (1.40 ) Weighted-average common shares outstanding - basic and diluted 111,019,647 93,746,243 110,559,113 93,759,894 June 30, 2025 December 31, 2024 Cash, cash equivalents, and investments $ 271,494 $ 372,336 Total assets 420,979 527,700 Total liabilities 66,768 64,466 Total stockholders' equity 354,211 463,234 View source version on Contacts InvestorsMeg Dodgemdodge@ MediaKevin Giordanomedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights
Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights

Yahoo

time28 minutes ago

  • Yahoo

Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights

Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE™ trial, and initiated global confirmatory Phase 3 study Planned del-zota BLA submission at year end 2025 for DMD44 on track to be Avidity's first BLA submission On track for three potential BLA submissions over a 12-month period Strong balance sheet and cash runway to mid-2027 enabling global commercial launch readiness; first potential commercial launch in U.S. in 2026 SAN DIEGO, Aug. 7, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) to profoundly improve people's lives, today reported financial results for the second quarter ended June 30, 2025 and highlighted recent progress. "Avidity continues to deliver on its leadership in RNA therapeutics as we prepare for three potential BLA submissions in a 12-month period with strong clinical data, regulatory progress, and operational execution," said Sarah Boyce, president and chief executive officer of Avidity. "Our programs in FSHD, DMD44 and DM1 each made meaningful advances during the second quarter of 2025, and we are encouraged by the consistent and reproducible data across these late-stage neuromuscular programs. We are keenly aware of the challenges facing patients and families living with these conditions and are preparing for potential commercialization with great thoughtfulness and urgency." "Avidity continues to operate from a position of financial strength," said Mike MacLean, chief financial officer at Avidity. "Avidity's recent topline data for del-brax continues to demonstrate the consistency of the platform. As we move quickly toward potentially three successive launches starting in 2026, we continue to make meaningful progress in building our global infrastructure." Company Highlights Delpacibart zotadirsen (del-zota) for the treatment of people living with Duchenne muscular dystrophy with mutations amenable to exon 44 skipping (DMD44): In July 2025, Avidity announced the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to del-zota Remain on track for planned BLA submission at year end 2025, which will be Avidity's first BLA Plan to present topline and functional data from the ongoing EXPLORE44-OLE™ trial in the fourth quarter of 2025 Delpacibart etedesiran (del-desiran) for the treatment of myotonic dystrophy type 1 (DM1): In July 2025, Avidity announced completion of enrollment in the ongoing Phase 3 HARBOR™ trial On track to share updates from the ongoing MARINA-OLE™ trial including long-term 4 mg/kg efficacy and safety data in the fourth quarter 2025 Expected publication of data analyses from the completed Phase 1/2 MARINA® trial (2025) Topline data readout from HARBOR™ study anticipated in the second quarter of 2026 Marketing application submissions for del-desiran including in U.S., E.U. and Japan anticipated to start in the second half of 2026 Delpacibart braxlosiran (del-brax) for the treatment of facioscapulohumeral muscular dystrophy (FSHD): In June 2025, Avidity announced multiple milestone updates for del-brax including: Alignment with FDA on accelerated and full approval pathways for del-brax; Positive topline Phase 1/2 FORTITUDE™ data from the dose escalation cohorts, demonstrating consistent improvement compared to placebo on multiple functional and quality of life measures, rapid and significant reductions in levels of KHDC1L or cDUX, a DUX4-regulated biomarker, and creatine kinase, a biomarker of muscle damage, and favorable long-term safety and tolerability; Initiated global, confirmatory FORTITUDE-3™ (formerly known as FORWARD™) study of del-brax 2 mg/kg every six weeks, intended to support Avidity's global approval strategy for del-brax Topline data from FORTITUDE biomarker cohort anticipated in the second quarter of 2026 Planned BLA submission for accelerated approval in the second half of 2026, using data from the ongoing, fully enrolled FORTITUDE biomarker cohort Second Quarter 2025 Financial Results Cash, cash equivalents and marketable securities totaled approximately $1.2 billion as of June 30, 2025 Following the end of the second quarter of 2025, the Company received net proceeds of $185.5 million from the sale of stock through its at-the-market offering program The Company expects that its cash, cash equivalents and marketable securities as of June 30, 2025, together with the net proceeds from the at-the-market offering, will be sufficient to fund its operations to mid-2027 Collaboration revenues were $3.8 million for the second quarter of 2025, compared to $2.0 million for the same period of 2024, and primarily relate to the recognition of revenues under Avidity's research collaboration and license partnership with Bristol Myers Squibb. Collaboration revenues were $5.4 million for the six months ended June 30, 2025, compared to $5.6 million for the same period of 2024, and primarily relate to Avidity's research collaboration and license partnership with Bristol Myers Squibb Research and development expenses for the second quarter of 2025 were $138.1 million, compared to $63.9 million for the same period of 2024. Research and development expenses for the six months ended June 30, 2025 were $237.6 million, compared to $130.8 million for the same period of 2024. The increases were primarily driven by the advancement of del-desiran, del-brax and del-zota, as well as internal and external costs related to the expansion of the company's overall research capabilities General and administrative expenses for the second quarter of 2025 were $36.9 million, compared to $20.7 million for the same period of 2024. General and administrative expenses for the six months ended June 30, 2025 were $70.5 million, compared to $34.6 million for the same period of 2024. The increases were primarily due to higher personnel and commercial infrastructure costs to support the company's expanded operations About Avidity Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is also advancing two wholly-owned precision cardiology development candidates addressing rare genetic cardiomyopathies. In addition, Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through key partnerships. Avidity is headquartered in San Diego, CA. For more information about our AOC platform, clinical development pipeline and people, please visit and engage with us on LinkedIn and X. Forward-Looking Statements Avidity cautions readers that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the company's current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: Avidity's plans for three potential product launches; Avidity's plans for BLA submissions for each of its product candidates and the timing thereof; the status of Avidity's ongoing clinical trials and cohorts therein, including but not limited to initiation, enrollment, design and goals; the ability for any of Avidity's product candidates to achieve accelerated approval; plans to present additional data, analyses and other updates from Avidity's ongoing clinical programs and the timing thereof; planned marketing applications for del-desiran in the U.S., European Union and Japan, and the timing thereof; the regulatory status of each of Avidity's clinical programs; Avidity's plans to become a global commercial organization and the status of its commercialization efforts; the characterization of data associated with Avidity's product candidates, the conclusions drawn therefrom, the reproducibility of such data, the impact of such data on the advancement of Avidity's product candidates and their abilities to treat their respective disease indication; Avidity's platform, planned operations and programs; and Avidity's cash position and runway. The inclusion of forward-looking statements should not be regarded as a representation by Avidity that any of these plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Avidity's business and beyond its control, including, without limitation: the data and results produced in Avidity's ongoing clinical trials as of the most recent respective cutoff dates may not be indicative of final results, may not support BLA submissions or accelerated approvals, may not be satisfactory to the FDA and other regulators, and new analyses of existing data and results may produce different conclusions than established as of the date hereof; even if approved, Avidity may not be able to execute any successful product launches; Avidity's efforts to build a global commercial organization may be unsuccessful; unexpected adverse side effects to, or inadequate efficacy of, Avidity's product candidates that may delay or limit their development, regulatory approval and/or commercialization; later developments with the FDA and other global regulators that could be inconsistent with the feedback received to date; Avidity's approach to the discovery and development of product candidates based on its AOC™ platform is unproven and may not produce any products of commercial value; potential delays in the commencement, enrollment, data readouts and completion of clinical trials; Avidity's dependence on third parties in connection with clinical testing and product manufacturing; legislative, judicial and regulatory developments in the United States and foreign countries; Avidity could exhaust its available capital resources sooner than it currently expects; and other risks described in Avidity's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and subsequent filings with the SEC. Avidity cautions readers not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the company undertakes no obligation to update such statements to reflect events that occur or circumstances that arise after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investor Contact:Kat Lange(619) 837-5014investors@ Media Contact:Kristina Coppola(619) 837-5016media@ Avidity Biosciences, Condensed Consolidated Financial Information(in thousands, except per share data)(unaudited)Statements of Operations Three Months Ended June 30,Six Months Ended June 30,2025202420252024 Collaboration revenue $ 3,847$ 2,045$ 5,420$ 5,588 Operating expenses:Research and development 138,12563,940237,615130,772 General and administrative 36,86420,73170,46434,629 Total operating expenses 174,98984,671308,079165,401 Loss from operations (171,142)(82,626)(302,659)(159,813) Other income, net 13,82711,83329,57120,165 Net loss $ (157,315)$ (70,793)$ (273,088)$ (139,648) Net loss per share, basic and diluted $ (1.21)$ (0.65)$ (2.11)$ (1.44) Weighted-average shares outstanding, basic and diluted 129,622106,928129,42897,070 Balance Sheets June 30,2025December 31,2024 AssetsCurrent assets:Cash, cash equivalents and marketable securities $ 1,183,144$ 1,501,497 Prepaid and other current assets 67,41640,793 Total current assets 1,250,5601,542,290 Property and equipment, net 20,53512,670 Restricted cash 2,7982,795 Right-of-use assets 4,2275,619 Other assets 90,806521 Total assets $ 1,368,926$ 1,563,895 Liabilities and Stockholders' EquityCurrent liabilities:Accounts payable and other liabilities $ 121,524$ 77,031 Deferred revenue, current portion 13,53720,987 Total current liabilities 135,06198,018 Lease liabilities, net of current portion 1,2102,957 Deferred revenue, net of current portion 39,99137,961 Total liabilities 176,262138,936 Stockholders' equity 1,192,6641,424,959 Total liabilities and stockholders' equity $ 1,368,926$ 1,563,895 View original content to download multimedia: SOURCE Avidity Biosciences, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store